|Molecular function||• receptor binding
• hormone activity
|Cellular component||• extracellular region
• extracellular space
• neuronal cell body
|Biological process||• apoptotic process
• signal transduction
• cell-cell signaling
• sensory perception of pain
• endocrine pancreas development
• negative regulation of cell differentiation
• negative regulation of bone resorption
|Sources: Amigo / QuickGO|
21.51 – 21.53 Mb
142.3 – 142.3 Mb
Amylin, or Islet Amyloid Polypeptide (IAPP), is a 37-residue peptide hormone. It is cosecreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1. Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.
IAPP is processed from an 89-residue coding sequence. Proislet Amyloid Polypeptide (proIAPP,Proamylin, Amyloid Polypeptide Precursor, Proislet Protein) is produced in the pancreatic beta cells (β-cells) as a 67 amino acid, 7404 Dalton pro-peptide and undergoes post-translational modifications including protease cleavage to produce amylin.
Other articles related to "amylin":
... Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insulin ... Like insulin, amylin is deficient in individuals with Type I diabetes ... By augmenting endogenous amylin, pramlintide aids in the absorption of glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1 ...
... Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987 ... Currently, Amylin produces three drugs, Symlin (pramlintide acetate) and Byetta (exenatide) and Bydureon (exenatide extended-release) ... Amylin also is working on producing analog of human leptin, metreleptin ...
... There appears to be at least three distinct receptor complexes that bind with high affinity to amylin ... All three complexes contain the calcitonin receptor at the core, plus one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3 ...
... On September 5, 2007, Kelaroo announced that it had expanded its contract research with Amylin Pharmaceuticals and received a strategic equity investment ... Kelaroo's proprietary SeqR(TM)technology was utilized to develop Amylin's PHINDER system for peptide hormone identification and optimization ...
... In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialize and manufacture a novel peptide therapeutic for the potential ... Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics ...